|
US928A
(en)
*
|
|
1838-09-19 |
|
Eccentbic bbake eob abbesting the motion of bailboad-cabs |
|
US3003323A
(en)
|
1958-01-29 |
1961-10-10 |
Armco Steel Corp |
Composite pile connector
|
|
US4626504A
(en)
|
1983-07-01 |
1986-12-02 |
Lubrizol Genetics, Inc. |
DNA transfer vector for gram-negative bacteria
|
|
SE8505027D0
(sv)
|
1985-10-24 |
1985-10-24 |
Kabigen Ab |
A lytic virulent phage, a hostcell containing same and a process for protein production
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
DE4208785A1
(de)
|
1992-03-19 |
1993-09-23 |
Degussa |
Verfahren zum auffinden von insertionselementen (is-elemente) oder transposonen
|
|
EP0665852A1
(en)
|
1993-07-09 |
1995-08-09 |
Amgen Boulder Inc. |
Recombinant ctla4 polypeptides and methods for making the same
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US20030049841A1
(en)
|
1997-06-16 |
2003-03-13 |
Short Jay M. |
High throughput or capillary-based screening for a bioactivity or biomolecule
|
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
ATE313341T1
(de)
|
2000-01-11 |
2006-01-15 |
Intralytix Inc |
Polymermischungen als bioabbaubare matrizen zur herstellung von biokompositen
|
|
WO2003060066A2
(en)
|
2001-11-07 |
2003-07-24 |
Musc Foundation For Research Development |
Nucleic acid delivery and expression
|
|
CA2396611A1
(en)
|
2002-07-31 |
2004-01-31 |
Plant Bioscience Limited |
Materials and methods for generating genetic disruptions in bacterial cells
|
|
HRP20120845T1
(hr)
|
2003-07-02 |
2012-11-30 |
Innate Pharma |
Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
|
|
HRP20170342T1
(hr)
|
2003-07-24 |
2017-05-19 |
Innate Pharma S.A. |
Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice
|
|
EP1677834B1
(en)
|
2003-10-06 |
2014-01-08 |
Gangagen, Inc. |
Defined dose therapeutic phage
|
|
AU2005324479A1
(en)
|
2004-04-07 |
2006-07-20 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Reporter plasmid phage packaging system for detection of bacteria
|
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
CN101103043A
(zh)
|
2005-01-06 |
2008-01-09 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
DK2341149T3
(en)
|
2005-08-26 |
2017-02-27 |
Dupont Nutrition Biosci Aps |
Use of CRISPR-associated genes (Cas)
|
|
CN101300272B
(zh)
|
2005-10-14 |
2013-09-18 |
依奈特制药公司 |
用于治疗增生性病症的组合物和方法
|
|
US8216996B2
(en)
|
2006-03-03 |
2012-07-10 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of cell surface functional molecule
|
|
US8445639B2
(en)
|
2006-05-15 |
2013-05-21 |
Avidbiotics Corporation |
Recombinant bacteriophage and methods for their use
|
|
EP2102350A4
(en)
*
|
2006-12-18 |
2012-08-08 |
Univ St Louis |
DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
|
|
CN105037549B
(zh)
|
2007-01-11 |
2018-09-28 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
|
CN101688241B
(zh)
|
2007-03-02 |
2015-01-21 |
杜邦营养生物科学有限公司 |
具有改善的噬菌体抗性的培养物
|
|
WO2008121830A2
(en)
|
2007-03-30 |
2008-10-09 |
National Research Council Of Canada |
Phage receptor binding proteins for antibacterial therapy and other novel uses
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
CN101970499B
(zh)
|
2008-02-11 |
2014-12-31 |
治疗科技公司 |
用于肿瘤治疗的单克隆抗体
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
WO2010011961A2
(en)
|
2008-07-25 |
2010-01-28 |
University Of Georgia Research Foundation, Inc. |
Prokaryotic rnai-like system and methods of use
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
US20100076057A1
(en)
|
2008-09-23 |
2010-03-25 |
Northwestern University |
TARGET DNA INTERFERENCE WITH crRNA
|
|
EP2367553B1
(en)
|
2008-12-05 |
2017-05-03 |
Novo Nordisk A/S |
Combination therapy to enhance nk cell mediated cytotoxicity
|
|
JP5344895B2
(ja)
*
|
2008-12-10 |
2013-11-20 |
矢崎総業株式会社 |
充電監視装置
|
|
WO2010075424A2
(en)
|
2008-12-22 |
2010-07-01 |
The Regents Of University Of California |
Compositions and methods for downregulating prokaryotic genes
|
|
US8241498B2
(en)
|
2009-03-28 |
2012-08-14 |
Phage Biocontrol Research, Llc |
Process for remediating biofouling in water systems with virulent bacteriophage
|
|
JP2010285425A
(ja)
|
2009-05-12 |
2010-12-24 |
Fujifilm Corp |
腸内細菌叢構成比率調整剤
|
|
BR112012007875A2
(pt)
|
2009-07-31 |
2016-11-22 |
Medarex Inc |
anticorpos totalmente humanos para btla
|
|
CA2772204A1
(en)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
HUE030100T2
(en)
|
2010-02-19 |
2017-04-28 |
Xencor Inc |
New CTLA4-IG immunoadhesins
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
US8252576B2
(en)
|
2010-08-11 |
2012-08-28 |
Phage Biocontrol Research, Llc |
Use of prokaryote viruses to remediate bio-fouling
|
|
CN103261213A
(zh)
*
|
2010-10-20 |
2013-08-21 |
杜邦营养生物科学有限公司 |
乳球菌CRISPR-Cas序列
|
|
EP2643350A4
(en)
|
2010-11-22 |
2015-01-07 |
Innate Pharma Sa |
TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US10512661B2
(en)
|
2011-02-04 |
2019-12-24 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
|
|
US10245288B2
(en)
|
2011-02-04 |
2019-04-02 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
|
|
US10835560B2
(en)
|
2013-12-20 |
2020-11-17 |
Joseph E. Kovarik |
Reducing the likelihood of skin cancer in an individual human being
|
|
US9730967B2
(en)
|
2011-02-04 |
2017-08-15 |
Katherine Rose Kovarik |
Method and system for treating cancer cachexia
|
|
US20180099001A1
(en)
|
2011-04-29 |
2018-04-12 |
Volant Holdings Gmbh |
Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
|
|
WO2012159023A2
(en)
|
2011-05-19 |
2012-11-22 |
Virginia Commonwealth University |
Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
|
|
ES2765874T3
(es)
|
2011-05-25 |
2020-06-11 |
Innate Pharma Sa |
Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
|
|
WO2012164565A1
(en)
|
2011-06-01 |
2012-12-06 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for downregulating prokaryotic genes
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
WO2013025119A1
(ru)
|
2011-08-18 |
2013-02-21 |
Roschin Evgeniy Mikhailovich |
Способ определения расположения протетической верхней плоскости у пациентов
|
|
US20130121968A1
(en)
|
2011-10-03 |
2013-05-16 |
Atossa Genetics, Inc. |
Methods of combining metagenome and the metatranscriptome in multiplex profiles
|
|
CN107858333B
(zh)
|
2011-10-28 |
2022-05-27 |
瑞泽恩制药公司 |
T细胞受体基因修饰小鼠
|
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
WO2013165921A2
(en)
|
2012-04-30 |
2013-11-07 |
Sonomaceuticals, Llc |
Therapeutic use of chardonnay seed products
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
WO2013187556A1
(en)
|
2012-06-14 |
2013-12-19 |
Scripps Korea Antibody Institute |
Novel antibody specific for clec14a and uses thereof
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
US10025647B2
(en)
|
2012-06-30 |
2018-07-17 |
Intel Corporation |
Memory poisoning with hints
|
|
US20150290244A1
(en)
|
2012-07-13 |
2015-10-15 |
The Trustees Of The University Of Pennsylvania |
Use of cart19 to deplete normal b cells to induce tolerance
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
US9460205B2
(en)
*
|
2012-07-20 |
2016-10-04 |
Google Inc. |
Crowdsourced video collaboration
|
|
AU2013293270B2
(en)
|
2012-07-25 |
2018-08-16 |
Massachusetts Institute Of Technology |
Inducible DNA binding proteins and genome perturbation tools and applications thereof
|
|
US9381244B2
(en)
|
2012-09-07 |
2016-07-05 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
|
DK2895012T3
(en)
|
2012-09-11 |
2018-01-22 |
Thylabisco Ab |
PREBIOTIC THYLAKOID COMPOSITION
|
|
JP2015528506A
(ja)
|
2012-09-13 |
2015-09-28 |
サリックス ファーマスーティカルズ，インコーポレーテッド |
体重減少及び肥満の治療のためのリファキシミンの投与の方法
|
|
US11060148B2
(en)
|
2012-10-16 |
2021-07-13 |
Dana-Farber Cancer Institute, Inc. |
Diagnosing and treating colorectal cancer
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
CA2898184A1
(en)
|
2013-01-16 |
2014-07-24 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
|
US10660943B2
(en)
|
2013-02-07 |
2020-05-26 |
The Rockefeller University |
Sequence specific antimicrobials
|
|
US11135273B2
(en)
*
|
2013-02-07 |
2021-10-05 |
The Rockefeller University |
Sequence specific antimicrobials
|
|
US9593339B1
(en)
*
|
2013-02-14 |
2017-03-14 |
David Gordon Bermudes |
Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
|
|
EP2971148A4
(en)
|
2013-03-14 |
2016-08-17 |
Seres Therapeutics Inc |
METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS
|
|
RU2662932C2
(ru)
|
2013-03-14 |
2018-07-31 |
Карибо Биосайенсиз, Инк. |
Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
US20140349400A1
(en)
|
2013-03-15 |
2014-11-27 |
Massachusetts Institute Of Technology |
Programmable Modification of DNA
|
|
WO2014165707A2
(en)
|
2013-04-03 |
2014-10-09 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
WO2014183066A2
(en)
|
2013-05-10 |
2014-11-13 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
CN105492611A
(zh)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
|
|
EP4023750A1
(en)
|
2013-07-01 |
2022-07-06 |
Massachusetts Institute of Technology |
Functionalization of endogenous bacteria
|
|
DE102013012448A1
(de)
|
2013-07-26 |
2015-01-29 |
Kuka Laboratories Gmbh |
Verfahren und Vorrichtung zum Bremsen einer Roboterachsanordnung
|
|
JP5729429B2
(ja)
*
|
2013-07-29 |
2015-06-03 |
トヨタ自動車株式会社 |
接合構造、及び接合構造の製造方法
|
|
AU2014296887A1
(en)
|
2013-08-02 |
2016-01-28 |
Aduro Biotech Holdings, Europe B.V. |
Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
|
|
US9944925B2
(en)
|
2013-08-02 |
2018-04-17 |
Enevolv, Inc. |
Processes and host cells for genome, pathway, and biomolecular engineering
|
|
WO2015021426A1
(en)
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
|
EP4074330A1
(en)
|
2013-09-05 |
2022-10-19 |
Massachusetts Institute of Technology |
Tuning microbial populations with programmable nucleases
|
|
US20150070747A1
(en)
*
|
2013-09-09 |
2015-03-12 |
Qualcomm Mems Technologies, Inc. |
Display element reset using polarity reversal
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
EP3988649B1
(en)
|
2013-09-18 |
2024-11-27 |
Kymab Limited |
Methods, cells and organisms
|
|
WO2015048577A2
(en)
*
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
KR102308597B1
(ko)
|
2013-10-17 |
2021-10-01 |
내셔널 유니버시티 오브 싱가포르 |
다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체
|
|
WO2015059690A1
(en)
|
2013-10-24 |
2015-04-30 |
Yeda Research And Development Co. Ltd. |
Polynucleotides encoding brex system polypeptides and methods of using s ame
|
|
US10752906B2
(en)
|
2013-11-05 |
2020-08-25 |
President And Fellows Of Harvard College |
Precise microbiota engineering at the cellular level
|
|
AU2014346846A1
(en)
|
2013-11-05 |
2016-06-09 |
Temple University Of The Commonwealth System Of Higher Education |
Polycationic amphiphiles as antimicrobial agents
|
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
WO2015070193A1
(en)
|
2013-11-11 |
2015-05-14 |
Liu Oliver |
Compositions and methods for targeted gene disruption in prokaryotes
|
|
CA2930877A1
(en)
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
|
EP2876167A1
(en)
|
2013-11-21 |
2015-05-27 |
Institut Gustave Roussy |
Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
|
|
US20150157670A1
(en)
*
|
2013-12-06 |
2015-06-11 |
K&K Ventures, LLC |
Non-caloric probiotic composition and method of preparation
|
|
KR102170502B1
(ko)
|
2013-12-11 |
2020-10-28 |
리제너론 파마슈티칼스 인코포레이티드 |
게놈의 표적화된 변형을 위한 방법 및 조성물
|
|
EP3470089A1
(en)
|
2013-12-12 |
2019-04-17 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
JP6712948B2
(ja)
*
|
2013-12-12 |
2020-06-24 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
|
|
US9676641B2
(en)
|
2014-01-29 |
2017-06-13 |
Synphagen Llc |
Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses
|
|
US10287590B2
(en)
|
2014-02-12 |
2019-05-14 |
Dna2.0, Inc. |
Methods for generating libraries with co-varying regions of polynuleotides for genome modification
|
|
CA2942245C
(en)
|
2014-03-12 |
2021-11-02 |
Yeda Research And Development Co. Ltd. |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
MX382033B
(es)
|
2014-03-19 |
2025-03-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
|
|
WO2015148680A1
(en)
*
|
2014-03-25 |
2015-10-01 |
Ginkgo Bioworks, Inc. |
Methods and genetic systems for cell engineering
|
|
EP3122880B1
(en)
*
|
2014-03-26 |
2021-05-05 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
|
CN106170550A
(zh)
|
2014-04-03 |
2016-11-30 |
麻省理工学院 |
用于产生导引rna的方法和组合物
|
|
JP2017512481A
(ja)
|
2014-04-08 |
2017-05-25 |
ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ |
Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
|
|
CN106536739B
(zh)
*
|
2014-04-14 |
2021-08-03 |
内梅西斯生物有限公司 |
治疗剂
|
|
GB201406968D0
(en)
|
2014-04-17 |
2014-06-04 |
Green Biologics Ltd |
Deletion mutants
|
|
GB201406970D0
(en)
|
2014-04-17 |
2014-06-04 |
Green Biologics Ltd |
Targeted mutations
|
|
WO2015189693A1
(en)
|
2014-06-12 |
2015-12-17 |
King Abdullah University Of Science And Technology |
Targeted viral-mediated plant genome editing using crispr/cas9
|
|
RU2715038C2
(ru)
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Антитела анти-pd-l1 и способы их диагностического применения
|
|
EP3186375A4
(en)
|
2014-08-28 |
2019-03-13 |
North Carolina State University |
Novel CAS9 PROTEINS AND CHARACTERISTICS FOR DNA TARGETING AND GENOME EDITING
|
|
US11274317B2
(en)
|
2014-09-05 |
2022-03-15 |
Vilnius University |
Targeted RNA knockdown and knockout by type III-A Csm complexes
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
JP2017529841A
(ja)
|
2014-09-19 |
2017-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ抗原受容体
|
|
WO2016063263A2
(en)
|
2014-10-23 |
2016-04-28 |
Institut Gustave Roussy |
Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
|
|
CN107208070B
(zh)
|
2014-11-26 |
2021-09-07 |
技术创新动力基金（以色列）有限合伙公司 |
细菌基因的靶向消除
|
|
WO2016183532A1
(en)
|
2015-05-13 |
2016-11-17 |
Synlogic, Inc. |
Bacteria engineered to treat a disease or disorder
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
US20160244784A1
(en)
|
2015-02-15 |
2016-08-25 |
Massachusetts Institute Of Technology |
Population-Hastened Assembly Genetic Engineering
|
|
JP7095993B2
(ja)
|
2015-03-02 |
2022-07-05 |
シンロジック オペレーティング カンパニー インコーポレイテッド |
消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌
|
|
CA2983236A1
(en)
|
2015-04-23 |
2016-10-27 |
Kaleido Biosciences, Inc. |
Glycan therapeutics and methods of treatment
|
|
GB2531454A
(en)
|
2016-01-10 |
2016-04-20 |
Snipr Technologies Ltd |
Recombinogenic nucleic acid strands in situ
|
|
EP3711488A1
(en)
|
2015-05-06 |
2020-09-23 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
|
US11883439B2
(en)
|
2015-05-13 |
2024-01-30 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat a disease or disorder
|
|
ES2881384T3
(es)
|
2015-05-13 |
2021-11-29 |
Synlogic Operating Co Inc |
Bacterias manipuladas para reducir la hiperfenilalaninemia
|
|
US20160347836A1
(en)
|
2015-05-28 |
2016-12-01 |
Bristol-Myers Squibb Company |
Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
|
|
EA201792663A1
(ru)
|
2015-05-29 |
2018-04-30 |
Норт Каролина Стейт Юниверсити |
Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
|
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
PE20180673A1
(es)
|
2015-06-01 |
2018-04-19 |
Univ Chicago |
Tratamiento contra el cancer por manipulacion de la microflora comensal
|
|
WO2016205276A1
(en)
|
2015-06-15 |
2016-12-22 |
North Carolina State University |
Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
|
|
US10648020B2
(en)
|
2015-06-18 |
2020-05-12 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
WO2016210384A2
(en)
|
2015-06-25 |
2016-12-29 |
Synlogic, Inc. |
Bacteria engineered to treat metabolic diseases
|
|
US20180200342A1
(en)
|
2015-07-13 |
2018-07-19 |
Institut Pasteur |
Improving sequence-specific antimicrobials by blocking dna repair
|
|
US20170216370A1
(en)
|
2015-07-31 |
2017-08-03 |
Synlogic, Inc. |
Bacteria engineered to treat disorders involving propionate catabolism
|
|
GB201514510D0
(en)
|
2015-08-14 |
2015-09-30 |
Nemesis Bioscience Ltd |
Delivery vehicle
|
|
KR102569754B1
(ko)
|
2015-09-10 |
2023-08-23 |
위니베르시트카솔리끄드루뱅 |
대사장애를 치료하기 위한 살균된 아커만시아의 용도
|
|
EP3356533A1
(en)
|
2015-09-28 |
2018-08-08 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
EP3368696A1
(en)
|
2015-10-30 |
2018-09-05 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
|
|
CN108513545B
(zh)
|
2015-11-20 |
2020-11-03 |
4D制药研究有限公司 |
包含细菌菌株的组合物
|
|
EP3384016A4
(en)
|
2015-12-04 |
2019-04-24 |
Massachusetts Institute of Technology |
MANIPULATED PHAGEMIDES
|
|
CU20180059A7
(es)
|
2015-12-17 |
2018-10-04 |
Gilead Sciences Inc |
Compuestos inhibidores de la quinasa de unión a tank
|
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
|
US10828318B2
(en)
|
2016-01-06 |
2020-11-10 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for treating malignant, autoimmune and inflammatory diseases
|
|
US20190010506A1
(en)
|
2016-01-11 |
2019-01-10 |
Synlogic, Inc. |
Bacteria engineered to treat metabolic diseases
|
|
US20190282628A1
(en)
|
2016-01-11 |
2019-09-19 |
Synlogic Inc. |
Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
|
|
WO2017123418A1
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Bacteria engineered to treat metabolic diseases
|
|
WO2017136795A1
(en)
|
2016-02-04 |
2017-08-10 |
Synlogic, Inc. |
Bacteria engineered to treat diseases associated with tryptophan metabolism
|
|
US20170247690A1
(en)
|
2016-02-25 |
2017-08-31 |
Agenovir Corporation |
Oncoviral treatment with nuclease and chemotherapeutic
|
|
WO2017152126A1
(en)
|
2016-03-03 |
2017-09-08 |
Cornell University |
Small molecule ire1-alpha inhibitors
|
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
EP3448400A4
(en)
|
2016-04-25 |
2019-11-13 |
Yale University |
BACTERIOPHAGE COMPOSITIONS AND USES THEREOF
|
|
US20190136230A1
(en)
|
2016-05-06 |
2019-05-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
KR102708641B1
(ko)
|
2016-09-27 |
2024-09-24 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
|
|
WO2018071536A1
(en)
|
2016-10-11 |
2018-04-19 |
Crestovo Holdings Llc |
Compositions and methods for treating primary sclerosing cholangitis and related disorders
|
|
US10626394B2
(en)
|
2016-10-28 |
2020-04-21 |
Massachusetts Institute Of Technology |
Synthetic bacteriophages and bacteriophage compositions
|
|
US11566238B2
(en)
|
2016-12-15 |
2023-01-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for modulating growth of a genetically modified gut bacterial cell
|
|
EP3559257A1
(en)
|
2016-12-22 |
2019-10-30 |
Institut Gustave Roussy (IGR) |
Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
|
|
US11149269B2
(en)
|
2017-05-15 |
2021-10-19 |
New York University |
Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability
|
|
EP3634442B1
(en)
|
2017-05-24 |
2025-04-09 |
Tets, Viktor, Veniaminovich |
Method for diagnosis of parkinson's disease
|
|
EP3634465A4
(en)
|
2017-05-25 |
2021-01-20 |
The Broad Institute, Inc. |
LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF
|
|
EP3630975B1
(en)
|
2017-05-26 |
2025-11-19 |
North Carolina State University |
Altered guide rnas for modulating cas9 activity and methods of use
|
|
WO2018222969A1
(en)
|
2017-06-02 |
2018-12-06 |
Board Of Regents, The University Of Texas System |
Specific bacterial species and metabolite that improves immune checkpoint inhibitor therapy efficacy
|
|
US11453874B2
(en)
|
2017-06-07 |
2022-09-27 |
The Rockefeller University |
Enhancement of CRISPR gene editing or target destruction by co-expression of heterologous DNA repair protein
|
|
JP2020525049A
(ja)
|
2017-06-25 |
2020-08-27 |
エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ |
微生物集団の変更及び細菌叢の改変
|
|
GB201710126D0
(en)
|
2017-06-25 |
2017-08-09 |
Snipr Tech Ltd |
Vectors & Methods
|
|
GB201712733D0
(en)
|
2017-08-08 |
2017-09-20 |
Snipr Tech Ltd |
Methods & cells
|
|
US10303379B2
(en)
|
2017-09-25 |
2019-05-28 |
International Business Machines Corporation |
Efficient adaptive read-ahead in log structured storage
|
|
US20190160120A1
(en)
|
2017-11-29 |
2019-05-30 |
Snipr Biome Aps |
Dna, methods etc
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
CA3099316A1
(en)
|
2018-05-04 |
2019-11-07 |
Locus Biosciences, Inc. |
Methods and compositions for killing a target bacterium
|
|
US12076352B2
(en)
|
2018-06-19 |
2024-09-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
|
US12203123B2
(en)
|
2018-10-01 |
2025-01-21 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
|
|
WO2020072254A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system and uses thereof for killing target cells
|
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
|
WO2020072250A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
|
|
US11851663B2
(en)
|
2018-10-14 |
2023-12-26 |
Snipr Biome Aps |
Single-vector type I vectors
|
|
US20220056457A1
(en)
|
2018-12-11 |
2022-02-24 |
The University Of Western Ontario |
Cis conjugative plasmid system
|
|
KR102227515B1
(ko)
|
2018-12-18 |
2021-03-12 |
주식회사 포스코 |
제올라이트 및 그 제조방법
|
|
GB201901099D0
(en)
|
2019-01-27 |
2019-03-13 |
Snipr Biome Aps |
Methods, uses and compositions
|
|
GB201912176D0
(en)
|
2019-08-23 |
2019-10-09 |
Snipr Biome Aps |
Plasmids
|
|
WO2021097118A1
(en)
|
2019-11-12 |
2021-05-20 |
The Broad Institute, Inc. |
Small type ii cas proteins and methods of use thereof
|
|
US20230235361A1
(en)
|
2020-07-03 |
2023-07-27 |
Eligo Bioscience |
Method of containment of nucleic acid vectors introduced in a microbiome population
|
|
GB202015255D0
(en)
|
2020-09-26 |
2020-11-11 |
Snipr Biome Aps |
Synthetic viruses
|
|
FR3136482A1
(fr)
|
2021-08-01 |
2023-12-15 |
Snipr Biome Aps |
Ingenierie du microbiote
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
KR20250031203A
(ko)
|
2022-06-29 |
2025-03-06 |
에스엔아이피알 바이옴 에이피에스. |
이 콜라이 세포의 표적화
|
|
GB202212688D0
(en)
|
2022-08-31 |
2022-10-12 |
Snipr Biome Aps |
A novel type of crispr/cas system
|
|
EP4677075A2
(en)
|
2023-03-06 |
2026-01-14 |
SNIPR Biome ApS |
Targeting cells in stressed growing conditions
|
|
GB202310227D0
(en)
|
2023-07-04 |
2023-08-16 |
Snipr Biome Aps |
Production & secretion of auxin-like molecules in bacteria
|